Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celsion initiates enrollment in Phase I/II breast cancer trial
The first patient treated in the Dignity trial was at Rhode Island Hospital by principal investigator Brigid O’Connor. The other clinical sites participating in the trial include: the
The first patient treated in the Dignity trial was at Rhode Island Hospital by principal investigator Brigid O’Connor. The other clinical sites participating in the trial include: the
Dr Smith has served as president of the Canadian Cardiovascular Society, chairman of the Scientific Review Committee of the Heart and Stroke Foundation of Canada, and president of
Pursuant to the terms of the agreement, the companies will jointly pursue world-wide business development opportunities with customers in the medical device market utilizing Covalon’s technologies. The companies
The program, active now at participating pharmacies, ensures patients with diabetes that their co-pay for Accu-Chek test strips will not exceed $25. The program provides a discount of
The study compared GI-5005 plus standard of care (SOC) – pegylated interferon and ribavirin – versus SOC alone in patients with chronic genotype 1 hepatitis C virus (HCV)
Aveo Pharmaceuticals has reported data from its preclinical models which demonstrates that the company’s potent and selective triple VEGF receptor inhibitor, AV-951, exhibits robust inhibitory activity in its
The Plus Phase IIa clinical trial was conducted in 32 chronic hepatitis C patients in the US who had failed prior treatment. The Plus trial was designed to
The trial will evaluate the dose and duration of treatment of R7128 in combination with Roche’s Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) – in hepatitis C virus (HCV)
Intarcia’s Phase I study is evaluating the safety and pharmacokinetics of ITCA 650 at several doses over a treatment period of four weeks. ITCA 650 therapy is administered
Immunomedics has reported results that indicate CD74 is expressed at high levels in the majority of gastrointestinal tumors, which may allow milatuzumab, the company’s humanized anti-CD74 antibody, to